Stock Events

Stock Events

Q/C Technologies 

$3.79
70
+$0.01+0.26% Tuesday 20:00

Statistics

Day High
3.87
Day Low
3.53
52W High
33.6
52W Low
2.5
Volume
298,719
Avg. Volume
-
Mkt Cap
15.79M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-54.32MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QCLS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap160.36B
Gilead Sciences is a biopharmaceutical company that competes with MyMD in the development of treatments for viral diseases, inflammatory and fibrotic diseases, which overlaps with MyMD's focus on immune-mediated diseases.
Abbvie
ABBV
Mkt Cap401.47B
AbbVie competes in the immunology and oncology sectors, directly challenging MyMD's efforts in developing therapies for immune system diseases and cancer.
AMGEN
AMGN
Mkt Cap188.67B
Amgen is a biotech firm focusing on novel therapies in areas like inflammation, which competes with MyMD's research into immune system modulation.
Bristol-Myers Squibb
BMY
Mkt Cap116.95B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer and immune system disorders, directly competing with MyMD's therapeutic areas.
Merck
MRK
Mkt Cap298.33B
Merck is known for its work in pharmaceuticals and vaccines, including treatments for immune system disorders, making it a competitor to MyMD.
Pfizer
PFE
Mkt Cap148.41B
Pfizer develops and manufactures drugs and vaccines, including for autoimmune diseases, competing with MyMD's focus on immune system modulation.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.62B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including immune-mediated diseases, directly competing with MyMD's focus areas.
Novartis
NVS
Mkt Cap284.61B
Novartis focuses on a broad range of healthcare areas, including advanced therapies in immunology and oncology, competing with MyMD.
Biogen
BIIB
Mkt Cap28.84B
Biogen focuses on neurology and rare diseases but also competes in the broader biopharmaceutical market against companies like MyMD.
Vertex Pharmaceuticals
VRTX
Mkt Cap113.41B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases in areas like cystic fibrosis, which involves modulation of the immune system, indirectly competing with MyMD.

About

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
Show more...
CEO
Mr. Joshua N. Silverman
Employees
6
Country
United States
ISIN
US62856X3008

Listings

F
DE
DQS.F
XNAS
US
QCLS
MU
DE
DQS.MU
BOATS
BOATS
QCLS.BOATS

0 Comments

Share your thoughts

FAQ

What is Q/C Technologies stock price today?▼
The current price of QCLS is $3.79 USD — it has increased by +0.26% in the past 24 hours. Watch Q/C Technologies stock price performance more closely on the chart.
What is Q/C Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Q/C Technologies stocks are traded under the ticker QCLS.
What is Q/C Technologies market cap?▼
Today Q/C Technologies has the market capitalization of 15.79M
What is Q/C Technologies revenue for the last year?▼
Q/C Technologies revenue for the last year amounts to 0 USD.
What is Q/C Technologies net income for the last year?▼
QCLS net income for the last year is -54.32M USD.
How many employees does Q/C Technologies have?▼
As of June 10, 2026, the company has 6 employees.
In which sector is Q/C Technologies located?▼
Q/C Technologies operates in the Health & Wellness sector.
When did Q/C Technologies complete a stock split?▼
The last stock split for Q/C Technologies was on September 02, 2025 with a ratio of 1:100.
Where is Q/C Technologies headquartered?▼
Q/C Technologies is headquartered in New York, United States.